Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: A phase II study with organ-sparing purposes

Oncology Reports

Volumn 10, Issue 3, 2003, Pages 759-766

  Mantovani, Giovanni ^a   Massa, Elena ^a   Astara, Giorgio ^a   Murgia, Viviana ^a   Gramignano, Giulia ^a   Ferreli, Luca ^a   Camboni, Paolo ^a   Lusso, Maria Rita ^a   Mocci, Miria ^a   Madeddu, Clelia ^a   Mura, Loredana ^a   Mudu, Maria Caterina ^a   Proto, Ernesto ^a   Tore, Giorgio ^b   Mura, Manfredi ^b   Macciò, Antonio ^c   Ferreli, Antonello ^d   Amichetti, Maurizio ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Medical Oncology Unit   (Italy)

^c Sirai Hospital   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

Author keywords

Chemoradiation therapy; Head and neck cancer; Induction chemotherapy; Organ function preservation; Stage IV

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTOKINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; LEPTIN; RETINOIC ACID; TAXOID;

ADULT; ARTICLE; BLOOD; CANCER STAGING; CLINICAL TRIAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; LEPTIN; MALE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; TAXOIDS; TREATMENT OUTCOME; TRETINOIN;

EID: 0642314276     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brockstein B and Vokes EE: Chemoradiotherapy for head and neck cancer. PPO Updates 10: 1-19, 1996.
2. Munro A: An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71: 83-91, 1995.
3. El-Sayed S and Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. 1 Clin Oncol 14: 838-847, 1996. (Pubitemid 26085529)
4. Vokes EE, Weichselbaum RR, Lippman S, et al: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
5. Stupp R and Vokes EE: Combined modality therapy of head and neck cancer. Semin Oncol 21: 349-358, 1994. (Pubitemid 24191594)
6. Dimery IW and Hong WK: Overview of combined modality therapy for head and neck cancer. J Natl Cancer Inst 85: 95-111, 1993.
7. Vokes EE and Weichselbaum RR: Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911-934, 1990. (Pubitemid 20148286)
8. Haffty BG, Son YH, Sasaku CT, et al: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 27: 241-250, 1993. (Pubitemid 23304449)
9. Fu KK, Phillips TL, Silverberg IY, et al: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. I Clin Oncol 5: 1410-1418, 1987. (Pubitemid 18049877)
10. Lo TC, Wiley AL Jr, Ansfield FJ, et al: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 126: 229-235, 1976.
11. Merlano M, Vitale V, Rosso R, et al: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327: 1115-1121, 1992.
12. Kies MS, Haraf DJ, Athanasiadis I, et al: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 16: 2715-2721, 1998. (Pubitemid 28363035)
13. Vokes EE, Moran WJ, Mick R, et al: Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol 7: 838-845, 1989. (Pubitemid 19172456)
14. Vokes EE, Choi KE, Schilsky RL, et al: Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6: 618-626, 1988.
15. Vokes EE, Weichselbaum RR, Mick R, et al: Favorable longterm survival following induction chemotherapy with PFL and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84: 877-882, 1992.
16. Vokes EE, Haraf DJ, McEvilly JM, et al: Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol 3: 79-81, 1992.
17. Vokes EE, Panje VR, Schilsky RL, et al: Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 7: 761-768, 1989. (Pubitemid 19145598)
18. Vokes EE, Haraf DJ, Mick R, et al: Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 12: 2351-2359, 1994. (Pubitemid 24346707)
19. Vokes EE, Kies M, Haraf DJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of disease. J Clin Oncol 13: 876-883, 1995.
20. Mantovani G, Gebbia V, Proto E, et al: Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer: a tentative quantitative evalutation of organ preservation and clinical response. Int J Oncol 9: 571-578, 1996. (Pubitemid 26323954)
21. Mantovani G, Gebbia V, Proto E, et al: Neo-adjuvant (primary) organ-preserving chemotherapy in the management of locally advanced laryngeal carcinoma: larynx preservation and clinical response. Int J Oncol 9: 1035-1043, 1996. (Pubitemid 26356450)
22. Mantovani G, Macciò A, Massa E, et al: Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation. Int J Oncol 16: 1227-1233, 2000.
23. Mantovani G, Proto E, Massa E, et al: Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol 20: 419-427, 2002.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
25. Mantovani G, Macciö A, Mura L, el at. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78: 554-561, 2000. (Pubitemid 32039615)
26. Mantovani G, Macciö A, Madeddu C, et al: Serum values of proinflammatory cytokines inversely correlate with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 79: 406-414, 2001. (Pubitemid 32692637)
27. Vokes EE, Kies MS, Haraf DJ, et al: Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18: 1652-1661, 2000. (Pubitemid 30220543)
28. Kies MS, Haraf DJ, Rosen F, et al: Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyper-fractioned radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19: 1961-1969, 2001. (Pubitemid 32702540)
29. Trotti A: Toxicity of organ preservation in head and neck cancer. ASCO 35th Annual Meeting, 1999. Educational Book. pp557-562, 1999.